

Resource Summary Report

Generated by T1D on Sep 5, 2026

US Biomax

RRID:SCR_004295

Type: Tool

Proper Citation

US Biomax (RRID:SCR_004295)

Resource Information

URL: <http://www.biomax.us/>

Proper Citation: US Biomax (RRID:SCR_004295)

Description: Our robust searchable Tissue Bank database at US Biomax contains normal, non-cancerous disease and cancer samples, just a fraction of total paraffin tissue bank. Use advanced search function to define your search. Some of them have H&E images. Our tissue repository, tissue bank has huge paraffin tissue blocks, a large selection of histology tissue section slides of human cancer, normal tissue, rhesus and cynomolgus normal fresh frozen tissue as well as paraffin blocks and slides. It has also normal human organs in paraffin embedded tissue blocks as well as rhesus and cynomolgus monkey normal organ tissues. Snap frozen (fresh frozen) tissue of rhesus/cynomolgus monkey are also available. We also provide tissue array, custom tissue microarray (with samples you provided or from our tissue bank) as well as OEM services. Other products/services available include tissue microarray, paraffin tissue sections, histology services and quantitative telomerase detection kit.

Abbreviations: US Biomax

Synonyms: US Biomax Inc.

Resource Type: biomaterial supply resource, material resource

Keywords: FASEB list

Resource Name: US Biomax

Resource ID: SCR_004295

Alternate IDs: nlx_31395

Record Creation Time: 20220129T080223+0000

Record Last Update: 20260904T000503+0000

Ratings and Alerts

No rating or validation information has been found for US Biomax.

No alerts have been found for US Biomax.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 93 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Hsu WW, et al. (2025) COL22A1 expression identifies aggressive glioma and independently predicts survival through integrated multiomics and clinical validation. *Discover oncology*, 16(1), 1945.

Liu T, et al. (2025) Dissecting PTPN7-driven aggressiveness in IDH-wildtype astrocytomas: multi-omics, clinical validation, and spatial transcriptomics for prognostic insights. *Discover oncology*, 16(1), 914.

Song WS, et al. (2025) TMEM106A as a Macrophage-Associated Biomarker of Prognosis in IDH-Wildtype Glioma: Integrative Multi-Omics and Spatial Analyses. *Cancer medicine*, 14(23), e71454.

Maurya SK, et al. (2025) Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 921.

Ramar V, et al. (2024) Interaction of NF- κ B and FOSL1 drives glioma stemness. *Cellular and molecular life sciences : CMLS*, 81(1), 255.

Panigrahi S, et al. (2024) Deciphering the role of endothelial granulocyte macrophage-CSF in chronic inflammation associated with HIV. *iScience*, 27(10), 110909.

Zhang X, et al. (2024) Unsupervised representation learning of chromatin images identifies changes in cell state and tissue organization in DCIS. *Nature communications*, 15(1), 6112.

Abrantes R, et al. (2024) Sialyl-Tn glycan epitope as a target for pancreatic cancer therapies. *Frontiers in oncology*, 14, 1466255.

Riscal R, et al. (2024) Bile Acid Metabolism Mediates Cholesterol Homeostasis and Promotes Tumorigenesis in Clear Cell Renal Cell Carcinoma. *Cancer research*, 84(10), 1570.

Chang PC, et al. (2023) Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma. *Cancer cell international*, 23(1), 62.

Gatenbee CD, et al. (2023) Virtual alignment of pathology image series for multi-gigapixel whole slide images. *Nature communications*, 14(1), 4502.

Cutano V, et al. (2023) LACTB exerts tumor suppressor properties in epithelial ovarian cancer through regulation of Slug. *Life science alliance*, 6(1).

Lin YC, et al. (2023) Decoding the prognostic significance of integrator complex subunit 9 (INTS9) in glioma: links to TP53 mutations, E2F signaling, and inflammatory microenvironments. *Cancer cell international*, 23(1), 154.

Xu M, et al. (2022) AHNAK2 is a biomarker and a potential therapeutic target of adenocarcinomas. *Acta biochimica et biophysica Sinica*, 54(11), 1708.

Das T, et al. (2022) USP15 and USP4 facilitate lung cancer cell proliferation by regulating the alternative splicing of SRSF1. *Cell death discovery*, 8(1), 24.

Prieto-Garcia C, et al. (2022) USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. *Molecular oncology*, 16(17), 3082.

Tsuji S, et al. (2022) Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer. *Cancer immunology research*, 10(8), 978.

Shmerling M, et al. (2022) LY6S, a New IFN-Inducible Human Member of the Ly6a Subfamily Expressed by Spleen Cells and Associated with Inflammation and Viral Resistance. *ImmunoHorizons*, 6(4), 253.

Mancini M, et al. (2021) Involvement of transcribed lncRNA uc.291 and SWI/SNF complex in cutaneous squamous cell carcinoma. *Discover oncology*, 12(1), 14.

Baek SM, et al. (2021) Senescence Marker Protein 30 (SMP30): A Novel Pan-Species Diagnostic Marker for the Histopathological Diagnosis of Breast Cancer in Humans and Animals. *International journal of molecular sciences*, 22(5).